PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH to Host Third Quarter 2017 Conference Call and Business Update on November 14, 2017
LYON, France --(BUSINESS WIRE)--Nov. 13, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (Nasdaq and Euronext : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will
View HTML
Toggle Summary ERYTECH to Host Third Quarter 2017 Conference Call and Business Update on November 14, 2017
LYON, France --(BUSINESS WIRE)--Nov. 13, 2017-- Regulatory News : ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Nasdaq and Euronext : ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced
View HTML
Toggle Summary Erytech Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
LYON, France --(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News : NOT FOR DISTRIBUTION IN AUSTRALIA , CANADA OR JAPAN ERYTECH Pharma (Paris:ERYP) (Euronext Paris: ERYP) (“ERYTECH” or “the Company”) announces trading resumption of its ordinary shares on Euronext Paris as from 4:00pm CET .
View HTML
Toggle Summary Erytech Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
LYON, France --(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News : NOT FOR DISTRIBUTION IN AUSTRALIA , CANADA OR JAPAN ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP) (“ERYTECH” or “the Company”) announces trading resumption of its ordinary shares on Euronext Paris as from 4:00pm CET
View HTML
Toggle Summary ERYTECH Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
LYON, France --(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News : NOT FOR DISTRIBUTION IN AUSTRALIA , CANADA AND JAPAN ERYTECH Pharma (Paris:ERYP) ("ERYTECH" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
View HTML
Toggle Summary ERYTECH Announces Pricing of Global Offering and Approval to List on Nasdaq Global Select Market
LYON, France --(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News : NOT FOR DISTRIBUTION IN AUSTRALIA , CANADA AND JAPAN ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) ("ERYTECH" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH Announces Trading Suspension of Its Ordinary Shares on Euronext Paris
LYON, France --(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News : NOT FOR DISTRIBUTION IN AUSTRALIA , CANADA OR JAPAN Trading in the ordinary shares of ERYTECH Pharma (Euronext Paris: ERYP) (“ERYTECH” or “the Company”) (Paris:ERYP) (ADR:EYRYY), was suspended at the request of the Company on
View HTML
Toggle Summary ERYTECH Announces Trading Suspension of Its Ordinary Shares on Euronext Paris
LYON, France --(BUSINESS WIRE)--Nov. 10, 2017-- Regulatory News : NOT FOR DISTRIBUTION IN AUSTRALIA , CANADA OR JAPAN Trading in the ordinary shares of ERYTECH Pharma (Euronext Paris: ERYP) (“ERYTECH” or “the Company”) (Paris:ERYP) (ADR:EYRYY), was suspended at the request of the Company on
View HTML
Toggle Summary ERYTECH Reports Third Quarter 2017 Financial Results and Provides Business Update
Presented full results of Phase 2b trial of eryaspase for the treatment of second-line metastatic pancreatic cancer at ESMO 2017 Congress and met with the U.S. Food & Drug Administration ( FDA ) to discuss plans for a proposed pivotal Phase 3 trial Resubmitted Marketing Authorization Application
View HTML
Toggle Summary ERYTECH Reports Third Quarter 2017 Financial Results and Provides Business Update
Presented full results of Phase 2b trial of eryaspase for the treatment of second-line metastatic pancreatic cancer at ESMO 2017 Congress and met with the U.S. Food & Drug Administration ( FDA ) to discuss plans for a proposed pivotal Phase 3 trial Resubmitted Marketing Authorization Application
View HTML
Top